Olema Pharmaceuticals Inc Dossier - Source-backed chat

Olema Pharmaceuticals Inc

OLMANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.65

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.27Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $723.6M

Enterprise Value $678M

Shares Outstanding 87.5M diluted

Next Earnings Date15 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Olema Pharmaceuticals is a high-conviction, clinical-stage oncology biotech poised for a transformative transition into a commercial-stage enterprise. The investment thesis is anchored by its lead asset, palazestrant (OP-1250), a potential best-in-class complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). Palazestrant is currently being evaluated in two pivotal Phase 3 trials: OPERA-01 (monotherapy in 2nd/3rd-line ER+/HER2- metastatic breast cancer) and OPERA-02 (in combination with ribociclib in frontline metastatic breast cancer). With a robust cash position of $505.3 million as of Q1 2026, providing a runway into mid-2028, Olema is well-funded to execute its clinical milestones. The upcoming Fall 2026 top-line data readout for OPERA-01 represents a major binary catalyst that could validate palazestrant's monotherapy profile and pave the way for an NDA filing in 2027. Additionally, encouraging early Phase 1 data for its KAT6 inhibitor, OP-3136, and a new clinical collaboration with Bayer highlight a growing pipeline with significant long-term optionality.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$39.30

High · most bullish analyst$59.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.0020%

The Phase 3 OPERA-01 trial fails to meet its primary PFS endpoint or demonstrates marginal efficacy that does not clearly differentiate palazestrant from standard-of-care therapies. Alternatively, unexpected safety concerns (e.g., severe neutropenia or gastrointestinal toxicities) emerge, severely limiting its commercial potential. This failure invalidates the monotherapy thesis, forcing the company to rely entirely on the longer-term OPERA-02 combination trial (readout in 2028) and early-stage OP-3136. The stock experiences a severe downward re-rating, and the cash runway is depleted more rapidly due to clinical restructuring.

Base CaseCentral scenario

$39.3050%

Matches the consensus mean

The Phase 3 OPERA-01 trial achieves positive top-line results in Fall 2026, demonstrating a statistically significant PFS benefit over standard-of-care endocrine therapy, consistent with Phase 1/2 historical data. Efficacy is observed in both ESR1-mutant and wild-type patients, supporting an NDA submission in 2027. The OPERA-02 trial continues to progress on schedule toward its 2028 readout. OP-3136 continues to show manageable safety and preliminary efficacy in Phase 1, supporting planned combination studies with palazestrant. Olema's cash runway remains sufficient to fund operations through mid-2028, minimizing near-term dilution risk.

Bull CaseUpside scenario

$59.0030%

The Phase 3 OPERA-01 trial meets its primary endpoint with statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care endocrine therapy, showing a superior safety profile with minimal grade 3/4 toxicities. This triggers a successful NDA filing in 2027 and commercial launch. Concurrently, the Phase 3 OPERA-02 trial continues rapid enrollment, and early combination data of palazestrant with ribociclib or other agents confirms its potential as the endocrine backbone of choice. OP-3136 demonstrates robust, durable anti-tumor activity in Phase 1 expansion cohorts, accelerating its development path.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Palazestrant (OP-1250) is a highly differentiated CERAN/SERD that completely blocks both AF1 and AF2 transcriptional activation domains, offering complete inhibition of ER-driven transcription regardless of ESR1 mutation status.
Strong balance sheet with $505.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing an operational runway into mid-2028.
Imminent high-impact binary catalyst with Phase 3 OPERA-01 monotherapy top-line results expected in Fall 2026.
Strategic clinical collaborations with major pharmaceutical companies, including Novartis (ribociclib supply for OPERA-02) and Bayer (evaluating OP-3136 with darolutamide in prostate cancer).
Promising early-stage pipeline optionality led by OP-3136, a selective KAT6 inhibitor that demonstrated acceptable tolerability and initial anti-tumor activity in its Phase 1 first-in-human study presented at ASCO 2026.

Key Investment Risks

High clinical development risk associated with late-stage oncology trials; failure of the Phase 3 OPERA-01 trial would severely damage the company's valuation and delay commercialization.
Intense competition in the endocrine-resistant breast cancer space from approved SERDs (e.g., elacestrant) and other oral SERDs/CERANs in development.
No current product revenues; the company is entirely dependent on external capital or future commercialization to achieve profitability, having reported a net loss of $162.5 million for the year ended December 31, 2025.
Combination therapy risks in the OPERA-02 trial, where efficacy and safety depend on the combinability of palazestrant with ribociclib, which may introduce cumulative toxicities.

Thesis Invalidation Triggers

Failure of the Phase 3 OPERA-01 trial to meet its primary endpoint of progression-free survival (PFS) with statistical significance.
Emergence of severe, unexpected treatment-related adverse events (TRAEs) in the OPERA-01 or OPERA-02 trials that compromise the safety profile of palazestrant.
A significant delay in the enrollment or execution of the Phase 3 OPERA-02 trial, pushing the expected top-line readout beyond 2028.
Inability to successfully initiate or advance the clinical collaboration with Bayer for OP-3136 in prostate cancer.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.